SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

MEDICINOVA INC
Date: Aug. 26, 2025 · CIK: 0001226616 · Accession: 0000000000-25-009159

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-289801

Date
August 26, 2025
Author
Division of
Form
UPLOAD
Company
MEDICINOVA INC

Letter

Re: MediciNova, Inc. Registration Statement on Form S-1 Filed August 22, 2025 File No. 333-289801 Dear Yuichi Iwaki:

August 26, 2025

Yuichi Iwaki President and Chief Executive Officer MediciNova, Inc. 4275 Executive Square, Suite 300 La Jolla, CA 92037

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: John E. Maciejewski, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 August 26, 2025

Yuichi Iwaki
President and Chief Executive Officer
MediciNova, Inc.
4275 Executive Square, Suite 300
La Jolla, CA 92037

 Re: MediciNova, Inc.
 Registration Statement on Form S-1
 Filed August 22, 2025
 File No. 333-289801
Dear Yuichi Iwaki:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Alan Campbell at 202-551-4224 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: John E. Maciejewski, Esq.
</TEXT>
</DOCUMENT>